SNRIs and reboxetine are associated with higher cardiovascular risk, SSRIs with lower risk, and agomelatine, mirtazapine, vilazodone, and vortioxetine with no current evidence of risk.
Systematic Review
Do newer antidepressants cause cardiovascular adverse effects?
SNRIs and reboxetine carry higher cardiovascular risk compared to SSRIs and other newer antidepressants, highlighting the need for careful selection in patients with cardiovascular concerns.
Newer antidepressants that are more selective in their neurotransmitter effects include the selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others (agomelatine, bupropion, mirtazapine, reboxetine, vilazodone, vortioxetine). This article systematically reviews data from a variety of sources regarding the potential adverse effects of these medications on various cardiovascular parameters. Potential biochemical mechanisms by which these antidepressants may adversely affect the cardiovascular system are also discussed. Antidepressants that are associated with higher cardiovascular risk (SNRIs, reboxetine), lower risk (SSRIs), and without current evidence of cardiovascular risk (agomelatine, mirtazapine, vilazodone, vortioxetine) are identified. The FDA's recommendations regarding citalopram are organized and summarized, and situations with higher risk of cardiovascular adverse effects are identified.
Mago et al. (Thu,) conducted a systematic review in Cardiovascular adverse effects of antidepressants. Newer antidepressants (SSRIs, SNRIs, and others) was evaluated on Cardiovascular adverse effects. SNRIs and reboxetine are associated with higher cardiovascular risk, SSRIs with lower risk, and agomelatine, mirtazapine, vilazodone, and vortioxetine with no current evidence of risk.